The stock of Eli Lilly and Company LLY has declined 1.7% already this week, losing almost $14 billion of its market value.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

STAT reporters discuss investors' interest in autoimmune disease, GLP-1 supply issues, and big moments from #STATSummit.

Ministers want to examine the impact of the weight loss drug tirzepatide on people’s health outcomes and employment status. Elisabeth Mahase looks at how the study will work A new partnership between ...

Britain will study whether the use of Eli Lilly’s weight loss drug can get people back into work and help tackle the high ...

It is primary aim is to analyse how tirzepatide, sold by Eli Lilly under the brand name Mounjaro, reduces obesity and other ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

Academic notes while Ozempic might prevent overdoses, weight loss drug may not actually reduce or end substance use ...

Hims & Hers is revolutionizing healthcare with affordable, convenient telehealth services, leading to a 260% stock increase in the last year. Read more here.

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

First patient dosed with ISP-001 shows reduced urinary GAG level, functional improvements surpassing enzyme replacement ...